ALISO VIEJO, Calif., April 17, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 64th Annual Meeting of the American Academy of Neurology (AAN), taking place in New Orleans, LA, at the Ernest N. Morial Convention Center from April 21 through 28, 2012.
Following are details about the data presentation:
Title: Burden of Pseudobulbar Affect Among Patients With Multiple Sclerosis, Stroke, and Brain Injury: Results From National Patient Surveys.Program Number: P03.153 (Poster Presentation)Presentation Date/Time: Tuesday, April 24, 2012, 5:00 p.m. Session Info: Session P03: Neurologic Manifestations of Systemic Disease: Imaging/EpidemiologyAbout Pseudobulbar AffectPeople with pseudobulbar affect (PBA) have sudden outbursts of involuntary crying or laughing, even though there may not be anything particularly sad or funny to trigger those emotions. Many people who suffer from PBA describe their episodes as uncontrollable, exaggerated, or different from their true feelings. PBA may occur when certain neurologic diseases or injury damage the areas of the brain that control normal expression of emotion. This damage can disrupt brain signaling, causing a "short circuit" and triggering episodes of involuntary crying or laughing. PBA can occur in people diagnosed with a variety of otherwise unrelated neurologic conditions such as Lou Gehrig's disease (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, traumatic brain injury (TBI), and Alzheimer's disease. For more information about PBA, please visit www.PBAinfo.org.
About Avanir Pharmaceuticals, Inc.Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.